Data Insights

Fibromun by Philogen for Leiomyosarcoma: Likelihood of Approval

Fibromun is under clinical development by Philogen and currently in Phase II for Leiomyosarcoma. According to GlobalData, Phase II drugs...

Likelihood of Approval and Phase Transition Success Rate Model - Fibromun in Leiomyosarcoma

Data Insights

Fibromun by Philogen for Soft Tissue Sarcoma: Likelihood of Approval

Fibromun is under clinical development by Philogen and currently in Phase III for Soft Tissue Sarcoma. According to GlobalData, Phase...

Likelihood of Approval and Phase Transition Success Rate Model - Fibromun in Soft Tissue Sarcoma

Data Insights

Fibromun by Philogen for Malignant Glioma: Likelihood of Approval

Fibromun is under clinical development by Philogen and currently in Phase II for Malignant Glioma. According to GlobalData, Phase II...

Likelihood of Approval and Phase Transition Success Rate Model - Fibromun in Malignant Glioma

Data Insights

Fibromun by Philogen for Glioblastoma Multiforme (GBM): Likelihood of Approval

Fibromun is under clinical development by Philogen and currently in Phase II for Glioblastoma Multiforme (GBM). According to GlobalData, Phase...

Likelihood of Approval and Phase Transition Success Rate Model - Fibromun in Glioblastoma Multiforme (GBM)

Data Insights

Fibromun by Philogen for Melanoma: Likelihood of Approval

Fibromun is under clinical development by Philogen and currently in Phase I for Melanoma. According to GlobalData, Phase I drugs...

Likelihood of Approval and Phase Transition Success Rate Model - Fibromun in Melanoma

Data Insights

Bifikafusp alfa + onfekafusp alfa by Philogen for Kaposi Sarcoma: Likelihood of Approval

Bifikafusp alfa + onfekafusp alfa is under clinical development by Philogen and currently in Phase II for Kaposi Sarcoma. According...

Data Insights

Bifikafusp alfa + onfekafusp alfa by Philogen for Keratoacanthoma: Likelihood of Approval

Bifikafusp alfa + onfekafusp alfa is under clinical development by Philogen and currently in Phase II for Keratoacanthoma. According to...

Data Insights

Bifikafusp alfa + onfekafusp alfa by Philogen for Cutaneous T-Cell Lymphoma: Likelihood of Approval

Bifikafusp alfa + onfekafusp alfa is under clinical development by Philogen and currently in Phase II for Cutaneous T-Cell Lymphoma....

Data Insights

Bifikafusp alfa + onfekafusp alfa by Philogen for Merkel Cell Carcinoma: Likelihood of Approval

Bifikafusp alfa + onfekafusp alfa is under clinical development by Philogen and currently in Phase II for Merkel Cell Carcinoma....

Data Insights

Bifikafusp alfa + onfekafusp alfa by Philogen for Cutaneous Squamous Cell Carcinoma (cSCC): Likelihood of Approval

Bifikafusp alfa + onfekafusp alfa is under clinical development by Philogen and currently in Phase II for Cutaneous Squamous Cell...

Data Insights

Bifikafusp alfa + onfekafusp alfa by Philogen for Basal Cell Carcinoma (Basal Cell Epithelioma): Likelihood of Approval

Bifikafusp alfa + onfekafusp alfa is under clinical development by Philogen and currently in Phase II for Basal Cell Carcinoma...

Data Insights

Fibromun by Philogen for Metastatic Melanoma: Likelihood of Approval

Fibromun is under clinical development by Philogen and currently in Phase II for Metastatic Melanoma. According to GlobalData, Phase II...

Data Insights

Darleukin by Philogen for Non-Small Cell Lung Cancer: Likelihood of Approval

Darleukin is under clinical development by Philogen and currently in Phase II for Non-Small Cell Lung Cancer. According to GlobalData,...

Data Insights

Fibromun by Philogen for Malignant Glioma: Likelihood of Approval

Fibromun is under clinical development by Philogen and currently in Phase II for Malignant Glioma. According to GlobalData, Phase II...

Data Insights

Fibromun by Philogen for Glioblastoma Multiforme (GBM): Likelihood of Approval

Fibromun is under clinical development by Philogen and currently in Phase II for Glioblastoma Multiforme (GBM). According to GlobalData, Phase...

Data Insights

Fibromun by Philogen for Melanoma: Likelihood of Approval

Fibromun is under clinical development by Philogen and currently in Phase I for Melanoma. According to GlobalData, Phase I drugs...

Data Insights

Dodekin by Philogen for Non-Small Cell Lung Cancer: Likelihood of Approval

Dodekin is under clinical development by Philogen and currently in Phase II for Non-Small Cell Lung Cancer. According to GlobalData,...

Likelihood of Approval and Phase Transition Success Rate Model - Dodekin in Non-Small Cell Lung Cancer

Data Insights

Dodekin by Philogen for Triple-Negative Breast Cancer (TNBC): Likelihood of Approval

Dodekin is under clinical development by Philogen and currently in Phase II for Triple-Negative Breast Cancer (TNBC). According to GlobalData,...

Likelihood of Approval and Phase Transition Success Rate Model - Dodekin in Triple-Negative Breast Cancer (TNBC)

Data Insights

Dodekin by Philogen for Melanoma: Likelihood of Approval

Dodekin is under clinical development by Philogen and currently in Phase II for Melanoma. According to GlobalData, Phase II drugs...

Likelihood of Approval and Phase Transition Success Rate Model - Dodekin in Melanoma

Data Insights

Fibromun by Philogen for Liposarcoma: Likelihood of Approval

Fibromun is under clinical development by Philogen and currently in Phase III for Liposarcoma. According to GlobalData, Phase III drugs...

Likelihood of Approval and Phase Transition Success Rate Model - Fibromun in Liposarcoma